Companies › Cardurion Pharmaceuticals
1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CRD-4730 Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor | CAMK2A, CAMK2B, CAMK2D, CAMK2G | Phase 2 | Catecholaminergic Polymorphic Ventricular Tachycardia; Heart Failure With Reduced Ejection Fraction (HFrEF) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06658899 | CRD-4730 | Phase 2 | Catecholaminergic Polymorphic Ventricular Tachycardia | Cardiovascular | Apr 2027 |
| NCT07750873 | CRD-4730 | Phase 2 | Heart Failure With Reduced Ejection Fraction (HFrEF) | Cardiovascular | Sep 2028 |
–
Nyrada AllRock Bio Zomagen Biosciences Agiana Pharmaceuticals Research Institute of Geroprotective Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.